Royal Bank Of Canada Forecasts Strong Price Appreciation for Definium Therapeutics (NASDAQ:DFTX) Stock

Definium Therapeutics (NASDAQ:DFTX) had its price objective hoisted by analysts at Royal Bank Of Canada from $57.00 to $66.00 in a research report issued on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Royal Bank Of Canada’s price objective suggests a potential upside of 48.92% from the stock’s current price.

Other research analysts have also issued reports about the company. Piper Sandler reiterated an “overweight” rating and set a $75.00 price objective (up from $73.00) on shares of Definium Therapeutics in a research report on Friday, August 7th. Canaccord Genuity Group set a $64.00 price target on shares of Definium Therapeutics in a research note on Thursday. Oppenheimer reaffirmed an “outperform” rating and set a $70.00 price target on shares of Definium Therapeutics in a research report on Wednesday. Robert W. Baird lifted their price objective on shares of Definium Therapeutics from $57.00 to $75.00 and gave the stock an “outperform” rating in a research note on Thursday. Finally, Leerink Partners set a $52.00 price objective on shares of Definium Therapeutics and gave the company an “outperform” rating in a report on Monday, June 22nd. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Definium Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $61.46.

Definium Therapeutics Stock Performance

Shares of NASDAQ:DFTX traded up $1.53 during trading on Thursday, reaching $44.32. 817,234 shares of the stock were exchanged, compared to its average volume of 2,289,230. Definium Therapeutics has a 12 month low of $8.70 and a 12 month high of $49.70. The firm has a market cap of $4.42 billion, a PE ratio of -12.92 and a beta of 2.23. The stock has a 50-day moving average price of $39.06 and a 200-day moving average price of $26.52. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04.

Definium Therapeutics (NASDAQ:DFTX) last announced its earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). Research analysts expect that Definium Therapeutics will post -2.81 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Matthew T. Wiley sold 2,867 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $129,101.01. Following the sale, the insider directly owned 174,633 shares of the company’s stock, valued at approximately $7,863,723.99. This represents a 1.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Robert Barrow sold 29,208 shares of the firm’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $1,315,236.24. Following the completion of the transaction, the chief executive officer owned 1,098,246 shares in the company, valued at $49,454,017.38. The trade was a 2.59% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 48,096 shares of company stock valued at $2,165,763. Company insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Definium Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in DFTX. Scientech Research LLC acquired a new stake in shares of Definium Therapeutics during the 3rd quarter worth approximately $286,000. Mercer Global Advisors Inc. ADV raised its position in Definium Therapeutics by 10.5% during the third quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock valued at $259,000 after purchasing an additional 2,079 shares in the last quarter. Virtu Financial LLC acquired a new position in Definium Therapeutics during the third quarter valued at approximately $379,000. Blair William & Co. IL lifted its stake in Definium Therapeutics by 43.6% during the third quarter. Blair William & Co. IL now owns 31,905 shares of the company’s stock worth $376,000 after purchasing an additional 9,687 shares during the last quarter. Finally, Cerity Partners LLC lifted its stake in Definium Therapeutics by 2.4% during the second quarter. Cerity Partners LLC now owns 49,650 shares of the company’s stock worth $322,000 after purchasing an additional 1,165 shares during the last quarter. 27.91% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium reported that its Phase 3 Voyage study showed DT120 produced a 5.4-point improvement in HAM-A anxiety scores versus placebo. The result represents the second positive late-stage study for the program and strengthens the case for regulatory approval and potential commercialization. Definium says LSD-based pill reduces anxiety in late-stage study
• Positive Sentiment: Coverage highlighted the positive Phase 3 results, with investor enthusiasm focused on DT120’s potential to address anxiety and disrupt the psychiatric-drug market. The company is also expected to provide additional data or updates ahead of a potential September 2026 catalyst. This LSD-Based Drug Just Scored Again. Definium Stock Soars.
• Positive Sentiment: Analysts raised their price targets following the trial update. Wells Fargo lifted its target from $68 to $72 and assigned an “overweight” rating, while Robert W. Baird raised its target from $57 to $75 with an “outperform” rating. Needham also increased its target from $50 to $66 and maintained a “buy” rating. These revisions imply substantial potential upside if DT120 succeeds commercially. Analyst price-target changes
• Neutral Sentiment: Trading in DFTX was temporarily halted for pending news on August 12, underscoring the market impact of the clinical announcement. Shares subsequently traded near the upper end of their 52-week range, reflecting heightened volatility and expectations.
• Negative Sentiment: HC Wainwright previously reduced its earnings forecasts across 2026-2030, including a deeper expected 2026 loss of $3.05 per share versus $2.10 previously and lower long-term estimates. Definium remains unprofitable, so valuation depends heavily on clinical execution, regulatory approval and DT120’s eventual commercial uptake.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.